Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
SPIRIVA RESPIMAT is a tiotropium bromide inhalation spray, a long-acting anticholinergic bronchodilator indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors in airway smooth muscle, causing bronchodilation and improved airflow.
Peak lifecycle with $924M in annual Part D spending signals a mature, well-established franchise with stable team structure and focus on market maintenance.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Worked on SPIRIVA RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$924M Medicare spend — this is a commercially significant brand
Working on SPIRIVA RESPIMAT offers stability and depth in a mature, high-revenue franchise ($924M annually) within respiratory care. Roles emphasize market defense, customer relationships, and operational excellence rather than innovation or launch activities.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo